This marks Keytruda's first approval for the given indication. Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Daina Graybosch has given his Buy rating due to a combination of factors, including the opinion that the recent sell-off of Merck’s stock, primarily due to the unexpected decline in Gardasil ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Is Merck a good buy right now? Investors can buy Merck's stock at a fairly reasonable multiple of 15 times next year's earnings (based on analyst estimates). It's a reasonably valued stock at a ...

How To Buy Merck & Company Shares By now you're likely curious about how to participate in the market for Merck & Co MRK – be it to purchase shares, or even attempt to bet against the company.